Clovis Oncology, Inc., a biotech formed by Pharmion execs to develop pancreas and lung cancer drugs, raised $130 million by offering 10 million shares at $13. It had originally filed to offer 9.3 million shares at a price range of $13 to $15. Clovis Oncology, Inc. plans to list on the NASDAQ under the symbol CLVS. J.P. Morgan and Credit Suisse acted as lead managers on the deal.
